- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04222491
Food Oral Immunotherapy for Peanut Allergy
October 17, 2023 updated by: Wayne G. Shreffler, MD, PhD, Massachusetts General Hospital
Outcomes of Clinical Food Oral Immunotherapy for Peanut Allergy
This is an open label observational single center study of clinical food oral immunotherapy outcomes with biomarker samples and participant and/or caregiver-completed questionnaires in participants between 6 months and 65 years of age with IgE-mediated peanut allergy undergoing food oral immunotherapy.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
In this research study the investigators want to learn more about the experience of participants with peanut allergy and their caregivers undergoing food oral immunotherapy (OIT) for peanut allergy.
Food oral immunotherapy (OIT) is a treatment for individuals with a food allergy to reduce the body's allergic response to the food allergen, resulting in fewer symptoms.
The treatment is also called desensitization.
An individual becomes desensitized to the food allergen by ingesting small amounts of the food that are slowly increased.
Over time, this helps the body's immune system become used to the food so that it no longer causes an allergic reaction.
By desensitizing to peanut, it may lower the risk of life-threatening allergic reactions and cause a decreased sensitivity to peanut.
The investigators specifically want to learn more about the effects of food OIT on quality of life and other outcomes important to participants with peanut allergy and their caregivers and to ultimately develop tests to predict who may respond favorably to food OIT.
Study Type
Interventional
Enrollment (Estimated)
500
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 65 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Individuals between 6 months and 65 years of age with a diagnosis of immunoglobulin E (IgE)-mediated peanut allergy and their caregivers; a diagnosis of IgE-mediated peanut allergy is defined by: (1) documented history of peanut allergy or determined to be allergic by oral food challenge; (2) evidence of peanut-specific IgE by either: positive skin prick test to peanut allergen (reaction wheal at least 3 mm larger than saline control) or serum peanut-specific IgE > 0.34 kilo-unit/liter (kU/L) or international unit/milliliter (IU/mL) at screening visit
- Referral by Massachusetts General Hospital (MGH) allergist for food oral immunotherapy
- Willing to sign informed consent or whose caregiver is willing to sign the informed consent (age appropriate)
- Willing to sign the assent form, if age appropriate
Exclusion Criteria:
- History of severe or life-threatening episode of anaphylaxis or anaphylactic shock within 60 days of screening
- Severe or poorly controlled asthma
- Diagnosis of other severe or complicating medical problems, including autoimmune or chronic immune inflammatory conditions or gastrointestinal inflammatory conditions, such as inflammatory bowel diseases and eosinophilic gastrointestinal disorders
- Current use of beta blocker medication(s)
- Inability to cooperate with and/or perform oral food challenge procedures
- Females who are pregnant, planning to become pregnant, or breastfeeding
- Investigator determination of safety concern for any reason
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: active peanut OIT
active peanut oral immunotherapy
|
Peanut oral immunotherapy for peanut allergy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of participants who tolerate the maintenance dose of 300 mg peanut protein with no symptoms within two years of starting OIT
Time Frame: 2 years
|
Feasibility analysis as assessed by the proportion of participants who tolerate the maintenance dose in a dichotomous manner
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in quality of life scores from baseline to end of treatment
Time Frame: 4 years
|
Change in quality of life scores from baseline assessment to end of treatment assessment using the Food Allergy Quality of Life Questionnaire (FAQLQ) total score.
The FAQLQ total and domain scores range from 1-7 where 1 was the best possible score (i.e.
fewest problems or better health related quality of life) and with the total score being the average of the domain scores.
The domains include Emotional Impact, Social and Dietary Restrictions, and Food Anxiety.
|
4 years
|
Change in peanut specific serum immunoglobulin E (IgE) from baseline to end of treatment
Time Frame: 4 years
|
Change in peanut specific serum immunoglobulin E (IgE) [in kilo-units per liter (kU/L) or international units per milliliter (IU/mL)] from baseline to end of treatment
|
4 years
|
Change in skin prick test reactivity to peanut extract from baseline to end of treatment
Time Frame: 4 years
|
Change in skin prick test wheal diameter measurement in millimeters to peanut extract from baseline to end of treatment
|
4 years
|
The proportion of participants who tolerate a cumulative dose of 5000 mg peanut protein on oral food challenge without treatment after 12 months on maintenance dose
Time Frame: 4 years
|
Desensitization to peanut as assessed by cumulative tolerated dose
|
4 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 4 years
|
Safety analysis as assessed by patient-reported or observed allergic symptoms that will be analyzed and tabulated
|
4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Wayne G Shreffler, MD, PhD, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 25, 2020
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
January 6, 2020
First Submitted That Met QC Criteria
January 7, 2020
First Posted (Actual)
January 10, 2020
Study Record Updates
Last Update Posted (Actual)
October 18, 2023
Last Update Submitted That Met QC Criteria
October 17, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019P003564
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peanut Allergy
-
Rima RachidUniversity of MinnesotaRecruitingPeanut Hypersensitivity | Peanut Allergy | Food Allergy | Food Allergy Peanut | Peanut-Induced Anaphylaxis | Allergy, PeanutUnited States
-
Scripps HealthThe Scripps Research InstituteWithdrawnFood Allergy PeanutUnited States
-
Novartis PharmaceuticalsTerminatedAllergy, PeanutUnited States, Germany, Japan, Australia, France, Spain, Denmark, Canada, Italy, Netherlands
-
University of ManitobaThe Hospital for Sick Children; University of British Columbia; McGill UniversityEnrolling by invitationAllergy to Peanut
-
Imperial College LondonUniversity of Sydney; National Institute for Health Research, United KingdomCompletedIgE Mediated Peanut AllergyUnited Kingdom
-
King's College LondonCharite University, Berlin, Germany; University Hospital, Bonn; Institut Curie; Levantine UKNot yet recruitingAllergy;Food | Food Allergy Peanut | Pathways and Sources of Exposure
-
Imperial College LondonUniversity College CorkActive, not recruitingPeanut Hypersensitivity | IgE Mediated Peanut AllergyUnited Kingdom
-
University of RochesterNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingEgg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut AllergyUnited States
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.; Novartis Pharmaceuticals; Rho Federal Systems Division, Inc.Active, not recruitingPeanut Allergy | Multi-food AllergyUnited States
-
Scott SichererNational Institute of Allergy and Infectious Diseases (NIAID)CompletedPeanut Allergy | Food AllergyUnited States
Clinical Trials on Peanut oral immunotherapy
-
Johns Hopkins UniversityCompleted
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)Completed
-
Guy's and St Thomas' NHS Foundation TrustKing's College London; Imperial College London; National Institute for Health...Unknown
-
Cambridge University Hospitals NHS Foundation TrustCompleted
-
Baylor College of MedicineCompletedPeanut Allergic SubjectsUnited States
-
University of North Carolina, Chapel HillCompletedFood HypersensitivityUnited States
-
Murdoch Childrens Research InstituteNot yet recruiting
-
Alton MeltonThe Cleveland ClinicActive, not recruiting
-
Assistance Publique - Hôpitaux de ParisDBV TechnologiesCompleted
-
University of North Carolina, Chapel HillGenentech, Inc.CompletedPeanut HypersensitivityUnited States